BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 18804046)

  • 1. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid generation of CMV pp65-specific T cells for immunotherapy.
    Bao L; Sun Q; Lucas KG
    J Immunother; 2007; 30(5):557-61. PubMed ID: 17589296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
    Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
    Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML; van Liempt E; Jedema I; Veltrop-Duits LA; Willemze R; Guchelaar HJ; Falkenburg JH; Meij P
    Cytotherapy; 2010 Nov; 12(7):933-44. PubMed ID: 20078388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.
    Albiero E; Amati E; Baumeister E; Einsele H; Grigoleit GU; Rodeghiero F
    J Immunother; 2016; 39(9):329-342. PubMed ID: 27631893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection.
    Gallez-Hawkins G; Thao L; Lacey SF; Martinez J; Li X; Franck AE; Lomeli NA; Longmate J; Diamond DJ; Spielberger R; Forman SJ; Zaia JA
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):890-902. PubMed ID: 16275592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
    Abu-Khader A; Krause S
    Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
    Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
    J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.
    Hebart H; Daginik S; Stevanovic S; Grigoleit U; Dobler A; Baur M; Rauser G; Sinzger C; Jahn G; Loeffler J; Kanz L; Rammensee HG; Einsele H
    Blood; 2002 May; 99(10):3830-7. PubMed ID: 11986243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
    Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
    J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
    Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
    J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy.
    Vaz-Santiago J; Lulé J; Rohrlich P; Kravtzoff R; Le Roy E; Davignon JL; Betbeder D; Davrinche C
    Cytotherapy; 2002; 4(1):11-9. PubMed ID: 11953037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
    Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
    J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.
    Gyulai Z; Endresz V; Burian K; Pincus S; Toldy J; Cox WI; Meric C; Plotkin S; Gönczöl E; Berencsi K
    J Infect Dis; 2000 May; 181(5):1537-46. PubMed ID: 10823751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
    Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM
    Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.